Biosimilars for the management of inflammatory bowel diseases: Economic considerations

L. Gulácsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna Vegh, Krisztina B. Gecse, Silvio Danese, Laurent Peyrin-Biroulet, P. Lakatos

Research output: Article

6 Citations (Scopus)

Abstract

Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians’ and patients’ skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.

Original languageEnglish
Pages (from-to)259-269
Number of pages11
JournalCurrent medicinal chemistry
Volume26
Issue number2
DOIs
Publication statusPublished - jan. 1 2019

Fingerprint

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Economics
Budgets
Health
Biological Therapy
Cost Savings
Therapeutics
Ulcerative Colitis
Crohn Disease
Health Status
Motivation
Costs
Sustainable development

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Biosimilars for the management of inflammatory bowel diseases : Economic considerations. / Gulácsi, L.; Pentek, Marta; Rencz, Fanni; Brodszky, Valentin; Baji, Petra; Vegh, Zsuzsanna; Gecse, Krisztina B.; Danese, Silvio; Peyrin-Biroulet, Laurent; Lakatos, P.

In: Current medicinal chemistry, Vol. 26, No. 2, 01.01.2019, p. 259-269.

Research output: Article

Gulácsi, L, Pentek, M, Rencz, F, Brodszky, V, Baji, P, Vegh, Z, Gecse, KB, Danese, S, Peyrin-Biroulet, L & Lakatos, P 2019, 'Biosimilars for the management of inflammatory bowel diseases: Economic considerations', Current medicinal chemistry, vol. 26, no. 2, pp. 259-269. https://doi.org/10.2174/0929867324666170406112304
Gulácsi, L. ; Pentek, Marta ; Rencz, Fanni ; Brodszky, Valentin ; Baji, Petra ; Vegh, Zsuzsanna ; Gecse, Krisztina B. ; Danese, Silvio ; Peyrin-Biroulet, Laurent ; Lakatos, P. / Biosimilars for the management of inflammatory bowel diseases : Economic considerations. In: Current medicinal chemistry. 2019 ; Vol. 26, No. 2. pp. 259-269.
@article{618d57d7799f40d98f7d3b518f0bd16c,
title = "Biosimilars for the management of inflammatory bowel diseases: Economic considerations",
abstract = "Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75{\%} lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians’ and patients’ skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.",
keywords = "Access to health services, Biosimilars, Budget impact, Cost-effectiveness, Crohn’s disease, Healthcare costs, Inflammatory bowel diseases, Ulcerative colitis",
author = "L. Gul{\'a}csi and Marta Pentek and Fanni Rencz and Valentin Brodszky and Petra Baji and Zsuzsanna Vegh and Gecse, {Krisztina B.} and Silvio Danese and Laurent Peyrin-Biroulet and P. Lakatos",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/0929867324666170406112304",
language = "English",
volume = "26",
pages = "259--269",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Biosimilars for the management of inflammatory bowel diseases

T2 - Economic considerations

AU - Gulácsi, L.

AU - Pentek, Marta

AU - Rencz, Fanni

AU - Brodszky, Valentin

AU - Baji, Petra

AU - Vegh, Zsuzsanna

AU - Gecse, Krisztina B.

AU - Danese, Silvio

AU - Peyrin-Biroulet, Laurent

AU - Lakatos, P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians’ and patients’ skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.

AB - Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians’ and patients’ skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.

KW - Access to health services

KW - Biosimilars

KW - Budget impact

KW - Cost-effectiveness

KW - Crohn’s disease

KW - Healthcare costs

KW - Inflammatory bowel diseases

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85063713426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063713426&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170406112304

DO - 10.2174/0929867324666170406112304

M3 - Article

C2 - 28393687

AN - SCOPUS:85063713426

VL - 26

SP - 259

EP - 269

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 2

ER -